Skip to main content

Table 2 The parameters of granule-mediated cytotoxic potential determined via flow cytometry analysis (Panel â„–2) in the blood and PitNETs tissue of two patients (patient P with primary disease, and patient R, who experienced a relapse)

From: Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases

 

Reference Intervals, Blood, %, n = 23, *n = 5

Patient P., blood, %

Patient R., blood October 2023, %

Patient R., blood February 2024, %

Patient R., blood April 2024, %

Patient P., PitNET, %

Patient R., PitNET, October 2023, %

Patient R., PitNET, April 2024, %

CD3-Perforin + cells out of all lymphocytes

5.4–16.1

8.74

2.34

7

9.95

9.06

0.67 < 

2.81

CD3-GranzymeB + cells out of all lymphocytes

4.7–15.3

7.06

1.64 < 

0.12 < 

0.19 < 

6.3

0.39 < 

4.57

CD3 + Perforin + cells out of all lymphocytes

4.3–13.3

10.8

8.69

3.57

1.12 < 

15.7

6.33

1.42

CD3 + GranzymeB + cells out of all lymphocytes

7.4–19.9

26.8

10.5

0.38 < 

0.86 < 

46.1 > 

3.65

6.43

Perforin + cells out of all lymphocytes (Sum)

12.7–26.5

19.54

11.03

10.57

11.07

24.76

7.0

4.22

GranzymeB + cells out of all lymphocytes (Sum)

14.4–32.9

33.9

12.14

0.5 < 

1.05 < 

52.4

4.04

11,0

GranzymeB + Perforin + cells out of CD3-NK-cells

72.1–91.0

64.3

66.3

4.39 < 

0.1 < 

46.9

11.8 < 

3.61 < 

CD3 + CD8 + T-cells out of all lymphocytes

21.7–30.5

37.1 > 

27.3

36.2 > 

38.1 > 

55.6

30.7

22.9

GranzymeB + Perforin + cells out of CD3 + CD8 + T-cells

6.5–30.3

69.9 > 

29.4

0.44 < 

0.09 < 

8.7 < 

2.87 < 

3.28

CD8 + Perforin + cytotoxicity index, %

22.5–48.9

30.2

25.2

12.4 < 

9.7 < 

30.2

21.9

26.8

CD8 + GranzymeB + cytotoxicity index, %

30.4–58.6

59.7

30.1

0.9

0.3. < 

63.3

25.5

24.5

CD16 + Perforin + cytotoxicity index, %

64.8–97.5

83.1

52.6

96.4

84.2

66.6

NA

10.5

CD16 + GranzymeB + cytotoxicity index, %

61.3–88.7

70.9

44.3 < 

1.6 < 

0.2 < 

55.2

35.4

18.2

CD56 + Perforin + cytotoxicity index, %

64.3–94.7

60.6

87.1

55.7

54

29

11.8

6.3

CD56 + GranzymeB + cytotoxicity index, %

61.3–93.1

52.5

74.8

1.5 < 

0.1 < 

56.1

27

8.2

CD3 + CD38 + from CD45 + lymphocytes

2.1–7.1*

3.68

2.51

1.52

6.04

54.5 > 

6.92

36.2 > 

CD3 + CD8 + CD38 + from CD3 + CD8 + T-cells

1.3–4.9*

1.88

4.15

2.3

4.15

74.8 > 

13.2

75.8 > 

CD3 + HLA-DR + from CD45 + lymphocytes

0.6–2.0*

8.46 > 

1.43

1.69

1.68

9.09

30.2

2.35

CD3 + CD8 + HLA-DR + from CD3 + CD8 + T-cells

0.3–2.7*

12.3 > 

3.37

1.05

2.6

5.07

5.54

6.11

CD8 + CD38 + from NK-cells

3.8–36.4*

18.5

7.64

6.96

17.2

8.82

NA

10.7

CD8 + CD38-from NK-cells

5.0–20.0*

4.35

23.1 > 

28.4 > 

18.2

5.88

NA

0.39

  1. Notations: > strong overperformance; < underperformance
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us